Nexus BioPharma, Inc. (OTCPK:NEXS) announced that it has entered into a securities purchase agreement for a private placement of 1 convertible promissory note for gross proceeds of $450,000 on March 8, 2017. The company issued 793,650 share purchase warrants with an aggregate exercise price of $0.14 or the lowest trade price in the 10 trading days previous to exercise. The note bears a $50,000 original issue discount. The warrants will have a five year expiration period from the date of issuance. The transaction included participation from new investor JMJ Financial. The notes are convertible at a 40% discount. The note will have a maturity period of 1 year and will bear a fixed interest rate of 12% per annum. The company may pre-pay with a 20% prepayment charge within 90 days and with a 40% prepayment charge within 180 days. The prepayment charge is in addition to the original issue discount and interest. The company may not pre-pay subsequent to 180 days. The note is unsecured in nature. The company will issue securities pursuant to exemption provided under Regulation D.